君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

未开盘 04-29 16:08:37

26.680

-0.560

-2.06%

最高27.980	最低26.340	成交量273.18万
今开27.980	昨收27.240	日振幅6.02%
总市值274.00亿	流通市值69.37亿	总股本10.27亿
成交额7,304万	换手率1.05%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":26.68,"timestamp":1777450117003,"preClose":27.24,"halted":0,"volume":2731800,"delay":0,"changeRate":-0.020558002936857517,"floatShares":260000000,"shares":1027000000,"eps":-0.87,"marketStatus":"未开盘","change":-0.56,"latestTime":"04-29 16:08:37","open":27.98,"high":27.98,"low":26.34,"amount":73040534,"amplitude":0.060206,"askPrice":26.68,"askSize":9200,"bidPrice":26.56,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-0.691,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777512600000},"marketStatusCode":0,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":27.24,"openAndCloseTimeList":[[1777426200000,1777435200000],[1777438800000,1777449600000]],"volumeRatio":0.497631,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":40.3,"timestamp":1777446000000,"preClose":41.36,"halted":0,"volume":14537600,"delay":0,"premium":"-42.19"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2631754596","title":"盈利在即二级市场却“不买单”，君实生物(01877)能否踏出估值修复关键一步？","url":"https://stock-news.laohu8.com/highlight/detail?id=2631754596","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631754596?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:49","pubTimestamp":1777456172,"startTime":"0","endTime":"0","summary":"4月27日，君实生物正式发布了2026Q1财报。在一季报披露次日，君实生物港股股价收涨4.45%，出现企稳反弹迹象。而在26Q1季度，君实生物实现收入7.26亿元，同比上涨45.09%，环比增长约5%;当期对应归母净利润同比大幅减亏91.24%。其中特瑞普利单抗当期销售收入为6.23亿元，2025年同期为4.47亿元，上涨了近40%。其中，JS207联合JS007一线治疗晚期肝细胞癌的II期研究是首次公布初步结果。而君实生物离新一轮估值修复与股价新高，或许只差重磅BD的临门一脚。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","BK1161","BK1583","BK1515","688180","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129898375","title":"异动解读 | 君实生物盘中大涨5.06%，一季度业绩超预期亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1129898375","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129898375?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:43","pubTimestamp":1777340623,"startTime":"0","endTime":"0","summary":"君实生物今日盘中股价大幅上涨5.06%，引起了市场的广泛关注。消息面上，公司发布的2026年第一季度财报显示业绩表现强劲。报告期内，公司实现营业收入7.26亿元，同比增长45.09%。更为关键的是，归属于上市公司股东的净亏损约为2056.4万元，较去年同期的2.35亿元大幅收窄91.24%，显示出公司正快速迈向盈亏平衡点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630347421","title":"港股君实生物绩后涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630347421","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630347421?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:40","pubTimestamp":1777340432,"startTime":"0","endTime":"0","summary":"4月28日，君实生物(01877.HK)绩后涨超3%，截至发稿，涨3.3%，报26.94港元，成交额923.16万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721673874.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721673874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK1161","01877","BK0239","VXUS","BK4585","BK1515","BK1583","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630347551","title":"减亏91%、现金流转正！君实生物靠什么摆脱“输血”依赖？","url":"https://stock-news.laohu8.com/highlight/detail?id=2630347551","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630347551?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:38","pubTimestamp":1777340280,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛4月27日晚间，君实生物（1877.HK，688180.SH）披露2026年第一季度报告。财报数据显示，君实生物2026年第一季度实现营业收入7.26亿元，同比增长45.09%；归母净利润亏损2056.4万元，较上年同期亏损2.35亿元大幅减亏91.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721589710.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721589710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","688180","159399","BK1515","BK0239","01877","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630106703","title":"图解君实生物一季报：第一季度单季净利润同比增长91.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630106703","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630106703?lang=zh_cn&edition=full","pubTime":"2026-04-28 04:35","pubTimestamp":1777322100,"startTime":"0","endTime":"0","summary":"证券之星消息，君实生物2026年一季报显示，一季度公司主营收入7.26亿元，同比上升45.09%；归母净利润-2056.4万元，同比上升91.24%；扣非净利润-1.44亿元，同比上升40.03%；负债率56.97%，投资收益1.21亿元，财务费用3585.71万元，毛利率79.76%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800012415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111490627","title":"君实生物第一季度营收7.26亿元，经调整净利润0.43亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111490627","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111490627?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:36","pubTimestamp":1777300587,"startTime":"0","endTime":"0","summary":"君实生物发布2026年第一季度财报。报告期内，公司实现营业收入7.26亿元，同比增长45.09%。经调整净利润为0.43亿元，同比增长2.78亿元。同期经营活动产生的现金流量净额约0.58亿元，较上年同期的负值有所改善。研发投入为2.82亿元，占营业收入的38.90%，较上年同期的70.03%有所下降。核心产品特瑞普利单抗注射液报告期内在国内市场实现销售收入约6.23亿元，同比增幅39.37%，为营收增长贡献主要动力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"君实生物第一季度营收7.26亿元，经调整净利润0.43亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630539011","title":"君实生物(01877)建议采纳2026年A股员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2630539011","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630539011?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:27","pubTimestamp":1777300020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)发布公告，于2026年4月27日，董事会决议批准采纳公司2026年A股员工持股计划。2026年A股员工持股计划须经公司股东会审议批准后方能生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688180","BK1161","BK1583","BK0239","159982","01877","BK1515","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117641748","title":"君实生物(01877)2025年收入同比增长28% 研发与国际化推进显著加速","url":"https://stock-news.laohu8.com/highlight/detail?id=1117641748","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117641748?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:36","pubTimestamp":1777282601,"startTime":"0","endTime":"0","summary":"君实生物于报告期内在香港联交所与内地科创板保持双重上市结构，共发行1,026,689,871股，包括260,295,700股H股及766,394,171股A股。管理层则在董事会领导下具体执行经营与研发战略。2025年公司实现收入人民币24.98亿元，较2024年度增长28%，主要由于药品销售带动。全年研发开支为人民币13.84亿元，同比增加9%，主要因在研管线和临床开发进程持续投入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"君实生物(01877)2025年收入同比增长28% 研发与国际化推进显著加速","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630364650","title":"君实生物：2025年净亏损8.48亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630364650","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630364650?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:36","pubTimestamp":1777282560,"startTime":"0","endTime":"0","summary":"南财智讯4月27日电，君实生物（01877.HK）公告，截至2025年12月31日止年度，公司总收入为24.98亿元人民币，同比增长28.23%；本公司拥有人应占年内亏损为8.48亿元人民币；每股基本亏损为0.84元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720272868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688180","BK1161","BK0239","01877","BK1515","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630097858","title":"每周股票复盘：君实生物（688180）新增募投项目实施主体","url":"https://stock-news.laohu8.com/highlight/detail?id=2630097858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630097858?lang=zh_cn&edition=full","pubTime":"2026-04-26 01:36","pubTimestamp":1777138571,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，君实生物报收于39.8元，较上周的45.04元下跌11.63%。本周关注点公司公告汇总：君实生物新增全资子公司作为募投项目部分子项目实施主体。国泰海通证券股份有限公司关于上海君实生物医药科技股份有限公司新增募投项目子项目实施主体的核查意见君实生物拟新增全资子公司宁波君研弘实生物医药科技有限公司作为2022年度向特定对象发行A股股票募投项目中“创新药研发项目”部分子项目的实施主体。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600000497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","01877","BK0239","BK1515","BK1583","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629830580","title":"4月23日增减持汇总：君实生物等4股拟减持，国创高新增持（表）","url":"https://stock-news.laohu8.com/highlight/detail?id=2629830580","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629830580?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:47","pubTimestamp":1776952020,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　据统计，4月23日，盘后，君实生物、奕帆传动、远东股份、中新集团在内的4家A股上市公司披露拟减持情况。国创高新披露增持情况。\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张乔松","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-04-23/doc-inhvpcuy3638599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","01877","BK0273","002377","BK0102","BK0239","BK1161","688180","BK1583","BK0190","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183803826","title":"君实生物股东上海探瀛拟通过大宗交易减持不超过2050万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1183803826","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183803826?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:45","pubTimestamp":1776948331,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司（以下简称\"君实生物\"）发布公告称，公司股东上海探瀛企业管理合伙企业计划通过大宗交易方式减持其持有的部分公司股份。\n根据减持计划，上海探瀛拟减持股份数量不超过2050万股，占公司总股本的一定比例。此次减持将通过大宗交易方式进行，减持期间将根据市场情况择机实施。\n市场分析人士指出，大宗交易减持通常对二级市场股价的直接影响相对较小，但投资者仍需关注股东减持背后的原因及后续动向。君实生物作为创新药企，其基本面及研发进展仍是影响长期股价表现的关键因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1515","BK1161","01877","688180","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629367148","title":"BNP PARIBAS SA减持君实生物(01877)51.02万股 每股作价27.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629367148","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629367148?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:31","pubTimestamp":1776943892,"startTime":"0","endTime":"0","summary":"4月20日，BNP PARIBAS SA减持君实生物(01877)51.02万股，每股作价27.6港元，总金额约为1408.15万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260423/20260423193204_96728.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260423/20260423193204_96728.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1161","688180","EWH","BK0239","BK1515","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629139835","title":"君实生物：股东上海檀英及贺铭拟合计减持不超2.09%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2629139835","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629139835?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:20","pubTimestamp":1776943258,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月23日，君实生物(688180.SH)公告称，股东上海檀英因基金期限与流动性资金安排，计划通过大宗交易方式减持不超过2053.38万股，占公司总股本的2%；股东贺铭因个人资金需求，计划通过集中竞价方式减持不超过88.26万股，占公司总股本的0.0860%。减持期间为自本公告披露之日起15个交易日后的三个月内。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604233716324143.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233716324143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1583","BK0239","688180","BK1515","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629095718","title":"中航证券：给予君实生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2629095718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629095718?lang=zh_cn&edition=full","pubTime":"2026-04-22 11:53","pubTimestamp":1776830032,"startTime":"0","endTime":"0","summary":"中航证券有限公司李蔚近期对君实生物进行研究并发布了研究报告《亏损持续收窄，商业化效率大幅提升》，给予君实生物买入评级。截至2025年年报披露日，特瑞普利单抗已在中国内地获批上市12项适应症，并全部纳入国家医保目录。　　风险提示：研发进度不及预期风险；商业化风险；财务风险；医药行业政策与市场波动风险最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为53.12。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200027197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","688180","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629372980","title":"君实生物（688180）披露新增部分募投项目子项目实施主体公告，4月21日股价下跌1.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629372980","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629372980?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:02","pubTimestamp":1776780142,"startTime":"0","endTime":"0","summary":"截至2026年4月21日收盘，君实生物报收于42.32元，较前一交易日下跌1.99%，最新总市值为434.5亿元。该股当日开盘43.56元，最高43.6元，最低41.79元，成交额达10.06亿元，换手率为3.09%。近日，君实生物发布《关于新增部分募投项目子项目实施主体的公告》。公告显示，公司拟新增全资子公司宁波君研弘实生物医药科技有限公司作为2022年度向特定对象发行A股股票募投项目中“创新药研发项目”部分子项目的实施主体。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100052552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688180","01877","BK1583","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628422097","title":"BNP PARIBAS SA减持君实生物(01877)112.64万股 每股作价26.31港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628422097","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628422097?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:07","pubTimestamp":1776683223,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，4月15日，BNP PARIBAS SA减持君实生物(01877)112.64万股，每股作价26.31港元，总金额约为2963.56万港元。减持后最新持股数目为2543.92万股，最新持股比例为9.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","EWH","BK0239","688180","BK1515","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174795594","title":"异动解读 | 君实生物盘中大涨5.11%，AACR数据披露与券商上调评级等多重利好共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1174795594","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174795594?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:45","pubTimestamp":1776649529,"startTime":"0","endTime":"0","summary":"君实生物今日盘中股价大幅上涨5.11%，市场表现活跃。消息面上，多重利好因素共同推动了股价上涨。其次，太平洋证券发布研报，上调公司目标价至53.12元，并给予“买入”评级。此外，公司第三大股东减持计划期满并未实施减持，叠加公司全年营收同比增长28.23%、核心产品特瑞普利单抗销售额增长超40%的积极财务表现，进一步提振了市场信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628799412","title":"迈威生物-B(02493)今起招股 君实生物、桂林三金及药明生物等基石认购5300万美元发售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2628799412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628799412?lang=zh_cn&edition=full","pubTime":"2026-04-20 06:34","pubTimestamp":1776638067,"startTime":"0","endTime":"0","summary":"2025年8月，迈利舒及迈卫健获巴基斯坦药品监管局上市批准。迈利舒及迈卫健是在巴基斯坦获批的首个Prolia及Xgeva生物类似药。于2024年及2025年，净亏损分别为约10.47亿元及9.72亿元，主要由于研发活动所产生的成本及开支。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1720050803.USD","LU0327786744.USD","SG9999002562.SGD","LU0348735423.USD","BK1589","BK1576","BK0188","BK1610","LU0417516902.SGD","LU1880383366.USD","BK0239","688062","LU1794554557.SGD","BK1161","LU0516423174.USD","688180","BK0028","LU0043850808.USD","LU0516422440.USD","LU0181495838.USD","LU1242518857.USD","LU0856984785.SGD","LU0326950275.SGD","LU0979878070.USD","LU0051755006.USD","LU0823426480.USD","01877","LU0572944931.SGD","LU3063872942.SGD","BK1583","LU0307460666.USD","BK1515","LU0456827905.SGD","02493","LU0052750758.USD","002275","LU0819121731.USD","LU0823426308.USD","LU0140636845.USD","BK0060","LU0516423091.SGD","LU0516422366.SGD","LU0588546209.SGD","LU0417516738.SGD","SG9999002463.SGD","02269","LU0456846285.SGD","LU2039709279.SGD","LU0039217434.USD","LU1688375341.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628975691","title":"每周股票复盘：君实生物（688180）将发布一季度未经审核业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2628975691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628975691?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:41","pubTimestamp":1776534068,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，君实生物报收于45.04元，较上周的38.08元上涨18.28%。本周，君实生物4月17日盘中最高价报45.48元。君实生物当前最新总市值462.42亿元，在生物制品板块市值排名4/51，在两市A股市值排名427/5198。公司公告汇总君实生物H股公告上海君实生物医药科技股份有限公司董事会谨定于2026年4月27日举行会议，以考虑及通过本集团截至2026年3月31日止三个月未经审核的财务业绩。公告同时列出了董事会成员名单，并注明了公告日期和发布人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1161","688180","BK0239","BK1515","01877"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":-0.0313},{"period":"1month","weight":0.2085},{"period":"3month","weight":0.1916},{"period":"6month","weight":0.087},{"period":"1year","weight":0.6253},{"period":"ytd","weight":0.2765}],"compareEarnings":[{"period":"1week","weight":-0.0305},{"period":"1month","weight":0.0292},{"period":"3month","weight":-0.0772},{"period":"6month","weight":-0.0229},{"period":"1year","weight":0.1688},{"period":"ytd","weight":0.0019}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.062525},{"month":3,"riseRate":0.75,"avgChangeRate":0.059343},{"month":4,"riseRate":0.875,"avgChangeRate":0.110904},{"month":5,"riseRate":0.428571,"avgChangeRate":0.004505},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.018268},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.014588},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.026161},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}